Cargando…
How to Manage a Patient with Ocular Metastases?
Ocular metastases are the most frequent ocular malignant tumors; their prevalence is estimated around 5–10% and is even higher in patients with breast or lung cancer. They represent various clinical situations, but they share the same hierarchical multidisciplinary therapeutic challenge with respect...
Autores principales: | , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
MDPI
2022
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9775125/ https://www.ncbi.nlm.nih.gov/pubmed/36551800 http://dx.doi.org/10.3390/biomedicines10123044 |
_version_ | 1784855567296102400 |
---|---|
author | Thariat, Juliette Boudin, Laurys Loria, Olivier Nguyen, Anh-Minh Kodjikian, Laurent Mathis, Thibaud |
author_facet | Thariat, Juliette Boudin, Laurys Loria, Olivier Nguyen, Anh-Minh Kodjikian, Laurent Mathis, Thibaud |
author_sort | Thariat, Juliette |
collection | PubMed |
description | Ocular metastases are the most frequent ocular malignant tumors; their prevalence is estimated around 5–10% and is even higher in patients with breast or lung cancer. They represent various clinical situations, but they share the same hierarchical multidisciplinary therapeutic challenge with respect to the way systemic and local therapies should be selected in combination or sequentially in the personalized medical history of a patient. The challenges include tumor control, eye preservation, and the minimization of iatrogenic damage to sensitive tissues surrounding the tumor in order to preserve vision. These aims should further contribute to maintaining quality of life in patients with metastases. Many patients with choroidal metastases have systemic molecular treatment for their primary tumor. However, secondary resistance to systemic treatment is common and may ultimately be associated with cancer relapse, even after an initial response. Therefore, it makes sense to propose local treatment concomitantly or after systemic therapy to provide a more sustainable response. The aim of this review is to present current therapeutic strategies in ocular metastases and discuss how to tailor the treatment to a specific patient. |
format | Online Article Text |
id | pubmed-9775125 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2022 |
publisher | MDPI |
record_format | MEDLINE/PubMed |
spelling | pubmed-97751252022-12-23 How to Manage a Patient with Ocular Metastases? Thariat, Juliette Boudin, Laurys Loria, Olivier Nguyen, Anh-Minh Kodjikian, Laurent Mathis, Thibaud Biomedicines Review Ocular metastases are the most frequent ocular malignant tumors; their prevalence is estimated around 5–10% and is even higher in patients with breast or lung cancer. They represent various clinical situations, but they share the same hierarchical multidisciplinary therapeutic challenge with respect to the way systemic and local therapies should be selected in combination or sequentially in the personalized medical history of a patient. The challenges include tumor control, eye preservation, and the minimization of iatrogenic damage to sensitive tissues surrounding the tumor in order to preserve vision. These aims should further contribute to maintaining quality of life in patients with metastases. Many patients with choroidal metastases have systemic molecular treatment for their primary tumor. However, secondary resistance to systemic treatment is common and may ultimately be associated with cancer relapse, even after an initial response. Therefore, it makes sense to propose local treatment concomitantly or after systemic therapy to provide a more sustainable response. The aim of this review is to present current therapeutic strategies in ocular metastases and discuss how to tailor the treatment to a specific patient. MDPI 2022-11-25 /pmc/articles/PMC9775125/ /pubmed/36551800 http://dx.doi.org/10.3390/biomedicines10123044 Text en © 2022 by the authors. https://creativecommons.org/licenses/by/4.0/Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (https://creativecommons.org/licenses/by/4.0/). |
spellingShingle | Review Thariat, Juliette Boudin, Laurys Loria, Olivier Nguyen, Anh-Minh Kodjikian, Laurent Mathis, Thibaud How to Manage a Patient with Ocular Metastases? |
title | How to Manage a Patient with Ocular Metastases? |
title_full | How to Manage a Patient with Ocular Metastases? |
title_fullStr | How to Manage a Patient with Ocular Metastases? |
title_full_unstemmed | How to Manage a Patient with Ocular Metastases? |
title_short | How to Manage a Patient with Ocular Metastases? |
title_sort | how to manage a patient with ocular metastases? |
topic | Review |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9775125/ https://www.ncbi.nlm.nih.gov/pubmed/36551800 http://dx.doi.org/10.3390/biomedicines10123044 |
work_keys_str_mv | AT thariatjuliette howtomanageapatientwithocularmetastases AT boudinlaurys howtomanageapatientwithocularmetastases AT loriaolivier howtomanageapatientwithocularmetastases AT nguyenanhminh howtomanageapatientwithocularmetastases AT kodjikianlaurent howtomanageapatientwithocularmetastases AT mathisthibaud howtomanageapatientwithocularmetastases |